ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Arcus Biosciences (RCUS)
Arcus Biosciences stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NYSE
$18.14▲ +2.14%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
45%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Arcus Biosciences in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Arcus Biosciences
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Arcus Biosciences a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $15.30 and $20.49; in 9 out of 10, between $11.80 and $26.56. Estimated annual volatility is 91%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $2.2B
- 52-week high
- $31.74
- 52-week low
- $17.43
- Revenue (12 months)
- $117M
- Revenue growth (YoY)
- -4.3%
- Gross margin
- 0.0%
- Operating margin
- -156.3%
- Net margin
- -142.9%
- Return on equity
- -90.8%
- Free cash flow (12 months)
- $-271M
- Beta
- 0.94
What this means
ATLAS does not publish a fair value for RCUS right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks RCUS has traded between $17.43 and $31.74. Today it is 42.8% below that high and 4% above its low.
On the business: revenue fell 4.3% year over year; net margin is 142.9%.
Its beta is 0.94: it moves roughly in line with the market.
About the company
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and combination medicines.
Want to see everything about Arcus Biosciences?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Arcus Biosciences do?
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and combination medicines.
What is the chance RCUS goes up next month?
45%: close to a coin flip. In half of the simulated outcomes, RCUS ends the month between $15.30 and $20.49.
How big is Arcus Biosciences and what is its P/E ratio?
Arcus Biosciences's market capitalization is $2.2B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is RCUS?
ATLAS estimates annual volatility at 91%. In a typical month, half of the outcomes end between $15.30 and $20.49.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer